Evoke Pharma, Inc. (EVOK)

$1

-0.06 (-5.66%)
Rating:
Recommendation:
Buy
Symbol EVOK
Price $1
Beta 0.359
Volume Avg. 0.01M
Market Cap 3.343M
Shares () -
52 Week Range 0.919-5.96
1y Target Est -
DCF Unlevered EVOK DCF ->
DCF Levered EVOK LDCF ->
ROE -263.21% Strong Sell
ROA -90.00% Strong Sell
Operating Margin -
Debt / Equity 938.54% Strong Buy
P/E -0.43 Neutral
P/B 6.21 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest EVOK news


Mr. David A. Gonyer R.Ph.
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.